Screener
4D Molecular Therapeutics FDMT Invested capital
Discontinued — last reported Q1 '26
Invested capital at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
FAQ
- What is 4D Molecular Therapeutics's invested capital?
- 4D Molecular Therapeutics (FDMT) reported invested capital of $399.88M in Q1 2026.
- How has 4D Molecular Therapeutics's invested capital changed year-over-year?
- 4D Molecular Therapeutics's invested capital increased by 11.1% year-over-year, from $360.05M to $399.88M.
- What is the long-term trend for 4D Molecular Therapeutics's invested capital?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's invested capital has grown at a 191.0% compound annual growth rate (CAGR), from -$2.24M to $466.84M.
- What does invested capital mean?
- Total debt plus shareholders' equity minus cash, at the quarter end. The capital actually put to work in the operating business — the denominator of return on invested capital (ROIC).
Ask your AI about 4D Molecular Therapeutics's invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude